Not finding it? Sign in to also search OpenAlex live.
-
Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.2024 Journal of Clinical Oncology conference-abstract Medicine PARP inhibition in cancer therapy Open access
Ilse A.C. Spiekman, Niven Mehra, Laurien Joanna Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, +10 more
3citations -
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
Rianne L Seefat, Sonja B. Vliek, Vincent M. T. de Jong, Sara Balduzzi, Ingrid A.M. Mandjes, Valesca P. Retèl, +38 more
2citations -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer2022 Annals of Oncology article Medicine PARP inhibition in cancer therapy Open access cited by 1 patent
Charles E. Geyer, Judy Ellen Garber, Richard D. Gelber, Greg Yothers, L. Ross, Priya Rastogi, +90 more
473citations -
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Maria De Santis, Sara Martínez Breijo, Paul J. Robinson, Camille Capone, Katie C Pascoe, Suzy Van Sanden, +6 more
10citations -
Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms2023 International Journal of Molecular Sciences article Medicine PARP inhibition in cancer therapy Open access
Max Bermes, María Jimena Rodriguez, Marcelo A. S. Toledo, Sabrina Ernst, Gerhard Müller‐Newen, Tim H. Brümmendorf, +3 more
7citations -
STING loss attenuates ISG expression without affecting PARP inhibitor sensitivity in Brca1+/− Jak2V617F MPN2026 Scientific Reports article Immunology and Microbiology interferon and immune responses Open access
Mirjam Hanako Sarholz, María Jimena Rodriguez, Tomasz Skórski, Steffen Koschmieder, Julian Baumeister
0citations -
Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.2023 Journal of Clinical Oncology conference-abstract Medicine Ovarian cancer diagnosis and treatment Open access
Petronella Beatrix Ottevanger, Judith R. Kroep, Els L. van Persijn-van Meerten, Anne M. van Altena, Cor Doede de Kroon, L. Ceton, +3 more
0citations -
Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays2020 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology BRCA gene mutations in cancer Open access
Peter Bouwman, Ingrid van der Heijden, Hanneke van der Gulden, Roebi de Bruijn, Merel E. Braspenning, Setareh Moghadasi, +3 more
39citations -
BRCA1/BARD1 ubiquitinates PCNA in unperturbed conditions to promote continuous DNA synthesis2024 Nature Communications article Biochemistry, Genetics and Molecular Biology DNA Repair Mechanisms Open access
Daniel Salas‐Lloret, Néstor García‐Rodríguez, Emily Soto-Hidalgo, Lourdes González-Vinceiro, Carmen Espejo-Serrano, Lisanne Giebel, +6 more
26citations